7th May 2021 14:08
GlaxoSmithKline PLC - Brentford, Middlesex-based pharmaceutical firm - GSK and Vir Biotechnology Inc say the European Medicines Agency has started a rolling review of test results for their Covid-19 treatment sotrovimab. The review is for use in people 12 years and older. A rolling review means the EMA will evaluate the test data on sotrovimab as it becomes available. A formal marketing authorisation application will be made once there is enough supporting evidence. Sotrovimab has not yet been granted marketing authorisation anywhere in the world, though an Emergency Use Authorization application has been submitted to the US Food & Drug Administration.
Current stock price: 1,350.80 pence
Year-to-date change: up 0.7%
By Tom Waite; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline